Monthly Oncology Tumor Boards: Advances in Multidisciplinary Management of Acute Myeloid Leukemia

June 17, 2021

Advances in the molecular understanding of acute myeloid leukemia (AML) have enhanced risk stratification and optimized therapeutic strategies. However, there is still a need for further refinement of current pre- and post-treatment risk stratification processes, and a need for additional treatment options for patients who have unfavorable cytogenetics or experience poor outcomes. Some novel treatment options are associated with improved clinical outcomes and fewer side effects than the conventional standard regimens. In many cases, there are unique adverse effects that require close monitoring and specialized supportive care. Clinicians need to be informed about these therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize current therapeutic agents being used in the management of AML.
  • Discuss emerging therapeutic agents and associated molecular targets being developed for AML management.
  • Review multidisciplinary supportive care considerations for current and emerging AML therapies.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Blueprint Medicines
  • Epizyme Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Sanofi Genzyme

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Illumina, Inc
  • Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. 

This activity is supported by an independent educational grant from Astellas.

This educational activity is supported by a medical education grant from Exelixis, Inc.
 

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
05/04/2021
Course expires: 
09/05/2021
Event starts: 
06/17/2021 - 12:00pm
Event ends: 
06/17/2021 - 1:00pm
Cost:
$0.00

Daniel A. Pollyea, MD, MS
University of Colorado Cancer Center

Glen J. Peterson, DNP, ACNP, RN
University of Colorado Cancer Center

Jennifer Tobin, PharmD, DPh
University of Colorado Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-042-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Thursday, June 17, 2021, from 12:00 – 1:00 PM Eastern Daylight Time (EDT) (UTC -4).  To adjust for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing